73230-98-5

Basic information

• Product Name: 3-methyl-N-(4-nitrophenyl)benzamide
• Synonyms: 3-Methyl-N-(4-nitrophenyl)benzamide; benzamide, 3-methyl-N-(4-nitrophenyl)-
• CAS NO: 73230-98-5
• Molecular Formula: C₁₄H₁₂N₂O₃
• Molecular Weight: 256.2567
• Mol File: 73230-98-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 355.5°C at 760 mmHg
• Flash Point: 168.8°C
• Density: 1.304g/cm³
• Vapor Pressure: 3.12E-05mmHg at 25°C
• Refractive Index: 1.656
• CAS DataBase Reference: 3-methyl-N-(4-nitrophenyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methyl-N-(4-nitrophenyl)benzamide(73230-98-5)
• EPA Substance Registry System: 3-methyl-N-(4-nitrophenyl)benzamide(73230-98-5)

Safety Data

• Hazardous Substances Data: 73230-98-5(Hazardous Substances Data)

Upstream product

• 100-01-6 4-nitro-aniline 
• 1711-06-4 3-Methylbenzoyl chloride 
• 99-04-7 m-Toluic acid 
• 62-53-3 aniline 
• 23099-05-0 3-methyl-N-phenylbenzamide 
• 73230-95-2 [(4-Nitro-phenylamino)-m-tolyl-methyl]-phosphonic acid diphenyl ester 

Downstream Products

• 425651-25-8 3-methyl-N-(4-aminophenyl)benzamide 

Relevant articles and documents

Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments

VEGF/VEGFR-2 signaling plays a critical part in tumor angiogenesis. Inhibition of this pathway has been considered as a promising approach for cancer treatment. In this work, a series of 6,7-dimethoxy-4-anilinoquinazoline derivatives bearing diarylamide moiety were designed, synthesized and evaluated as potent inhibitors of VEGFR-2 kinase. Their in vitro antiproliferation activities against two human cancer cell lines Hep-G2 and MCF-7 have also been determined. Among them, compound 14b exhibited the most potent inhibitory activity against VEGFR-2 with IC50 value of 0.016 ± 0.002 μM and it showed the most potent antiproliferative effect against Hep-G2 and MCF-7 with IC50 values at low-micromolar range. Molecular docking studies revealed that these compounds represented by the most potent compound 14b could bind well to the ATP-binding site of VEGFR-2, which suggested that compound 14b could be a potential anticancer agent targeting VEGFR-2.

Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment

Overexpression of EGFR is often associated with advanced stage disease and poor prognosis. In certain cancers, Src works synergistically with EGFR to promote proliferation, survival, invasion and metastasis. Development of dual-target drugs against EGFR and Src is of therapeutic advantage against these cancers. Based on molecular docking and our previous studies, we rationally designed a new series of azaacridine derivatives as potent EGFR and Src dual inhibitors. Most of the synthesized azaacridines displayed good antiproliferative activity against K562 and A549?cells. The representative compound 13b showed nM IC50 values against K562 and A549?cells, and inhibited EGFR at inhibition rate of 33.53% at 10?μM and Src at inhibition rate of 72.12% at 1?μM. Furthermore, compound 13b could inhibit the expression of EGFR, p-EGFR, Src and p-Src. Moreover, 13b efficiently inhibited the invasion of tumor cells and induced cancer cells apoptosis. Our study suggested that azaacridine scaffold can be developed as novel multi-target kinase inhibitors for cancer therapy.

Diarylurea histone deacetylation enzyme inhibitor

The invention belongs to the field of medical chemistry and particularly relates to a diarylurea histone deacetylation enzyme inhibitor, a medicine composition containing the histone deacetylation enzyme inhibitor, application of the inhibitor to preparat